OMALIZUMAB

Indications & Dose:

Prophylaxis of severe persistent allergic asthma

• BY SUBCUTANEOUS INJECTION

Adult: Dose according to immunoglobulin E concentration and body-weight (consult product literature) Add-on therapy for chronic spontaneous urticaria in patients who have had an inadequate response to H1 antihistamine treatment

• BY SUBCUTANEOUS INJECTION

Adult: 300 mg every 4 weeks 

Contraindications:

 Breast feeding, Acute asthama, bronchospasm, status asthematicus

Side Effects:

Common or very common Abdominal pain . arthralgia . headache . injection-site reactions . pyrexia . sinusitis . upper respiratory tract infection Uncommon Bronchospasm . cough . diarrhoea . dizziness . drowsiness . dyspepsia . flushing . influenza-like illness .

malaise . nausea . paraesthesia . pharyngitis . photosensitivity . postural hypotension . pruritus . rash . syncope . urticaria . weight gain

Rare Angioedema . antibody formation . laryngoedema . parasitic infection

Frequency not known Alopecia . arterial thromboembolic events . Churg-Strauss syndrome . joint swelling . myalgia . serum sickness (including fever and lymphadenopathy) . thrombocytopenia

Cautions:

Autoimmune disease . susceptibility to helminth infection—discontinue if infection does not respond to anthelmintic 

Precautions:

Interaction:

Warnings:

Adverse Effects:

Lactations:

Special Precautions:

Counselling:

Side Effects Or Adverse Reactions:

Patient And Carer Advice: